BRPI0610968A2 - composição de sangue de cordão umbilical, e, métodos para tratar uma doença maligna ou distúrbio benigno associado com o sistema hemoatopoiético e para preparar uma composição de sangue umbilical - Google Patents

composição de sangue de cordão umbilical, e, métodos para tratar uma doença maligna ou distúrbio benigno associado com o sistema hemoatopoiético e para preparar uma composição de sangue umbilical

Info

Publication number
BRPI0610968A2
BRPI0610968A2 BRPI0610968-3A BRPI0610968A BRPI0610968A2 BR PI0610968 A2 BRPI0610968 A2 BR PI0610968A2 BR PI0610968 A BRPI0610968 A BR PI0610968A BR PI0610968 A2 BRPI0610968 A2 BR PI0610968A2
Authority
BR
Brazil
Prior art keywords
blood composition
ucb
hemoatopoietic
treating
methods
Prior art date
Application number
BRPI0610968-3A
Other languages
English (en)
Inventor
Chow Robert
Original Assignee
Stemcyte, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37482333&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0610968(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Stemcyte, Inc. filed Critical Stemcyte, Inc.
Publication of BRPI0610968A2 publication Critical patent/BRPI0610968A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/10—Preservation of living parts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/51—Umbilical cord; Umbilical cord blood; Umbilical stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Developmental Biology & Embryology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Dentistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Environmental Sciences (AREA)
  • AIDS & HIV (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Reproductive Health (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

composição de sangue de cordão umbilical, e, métodos para tratar uma doença maligna ou distúrbio benigno associado com o sistema hemoatopoiético e para preparar uma composição de sangue de cordão umbilical as composições de sangue de cordão umbilical (ucb) da presente invenção compreendem as características únicas de apresentarem plasma que é substancialmente depletado da unidade de ucb e células sanguíneas vermelhas (rbc) que não são depletadas da unidade de ucb. referidas unidades de ucb podem ser preparadas por meio de um processo que combina depleção de plasma com crioconservação, seleção, descongelamento, e/ou transplante de células-tronco hematopoiéticas proporcionando resultado clínico superior mediante a maximização da recuperação de células após o processamento e dose de células de infusão após o descongelamento. proporciona-se também métodos para tratamento de uma ampla variedade de doenças malignas e de doenças benignas associadas com o sistema hemoatopoiético mediante administração de composições de ucb da presente invenção.
BRPI0610968-3A 2005-06-02 2006-06-02 composição de sangue de cordão umbilical, e, métodos para tratar uma doença maligna ou distúrbio benigno associado com o sistema hemoatopoiético e para preparar uma composição de sangue umbilical BRPI0610968A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US68712705P 2005-06-02 2005-06-02
US60/687127 2005-06-02
US73395605P 2005-11-03 2005-11-03
US60/733956 2005-11-03
PCT/US2006/021405 WO2006130812A2 (en) 2005-06-02 2006-06-02 Plasma-depleted, non-red blood cell-depleted cord blood compositions and methods of use

Publications (1)

Publication Number Publication Date
BRPI0610968A2 true BRPI0610968A2 (pt) 2019-05-14

Family

ID=37482333

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0610968-3A BRPI0610968A2 (pt) 2005-06-02 2006-06-02 composição de sangue de cordão umbilical, e, métodos para tratar uma doença maligna ou distúrbio benigno associado com o sistema hemoatopoiético e para preparar uma composição de sangue umbilical

Country Status (11)

Country Link
EP (1) EP1906729B1 (pt)
JP (1) JP2008545755A (pt)
KR (1) KR20080027295A (pt)
AT (1) ATE551062T1 (pt)
AU (1) AU2006252363A1 (pt)
BR (1) BRPI0610968A2 (pt)
CA (1) CA2609266A1 (pt)
IL (1) IL187641A0 (pt)
MX (1) MX2007015201A (pt)
RU (1) RU2007148802A (pt)
WO (1) WO2006130812A2 (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101707891A (zh) * 2007-03-28 2010-05-12 热起源公司 从骨髓或脐带血回收的干细胞和祖细胞组合物；用于制备其的系统和方法
RU2343928C1 (ru) * 2007-04-03 2009-01-20 Открытое акционерное общество "Институт стволовых клеток человека" Способ получения ядросодержащих клеток из пуповинной крови
SG193888A1 (en) * 2008-09-03 2013-10-30 Mesoblast Inc Expansion of haemopoietic precursors
EP3590520B1 (en) * 2010-04-09 2021-12-29 Fred Hutchinson Cancer Research Center Compositions for providing hematopoietic function without hla matching
EP3097916B1 (en) * 2010-04-09 2021-07-07 Fred Hutchinson Cancer Research Center Compositions and methods for providing hematopoietic function
JP5899246B2 (ja) * 2011-02-18 2016-04-06 ステムサイト インコーポレーテッドＳｔｅｍｃｙｔｅ，Ｉｎｃ． 幹細胞の包装製品並びに同包装製品を作製する方法および輸送する方法
US9943545B2 (en) * 2013-03-15 2018-04-17 Fate Therapeutics, Inc. Stem cell culture media and methods of enhancing cell survival
WO2016076428A1 (ja) 2014-11-14 2016-05-19 日本赤十字社 臍帯血および末梢血の凍結保存方法および凍結保存用溶液
RU2590688C2 (ru) * 2014-11-19 2016-07-10 Публичное акционерное общество "Институт Стволовых Клеток Человека" Способ получения суспензии ядросодержащих клеток из пуповинной крови со стандартизированной концентрацией
SG11201707134WA (en) * 2015-03-06 2017-10-30 Ajou Univ Industry-Academic Coop Found Cell therapeutic agent for cancer treatment and combination therapy with same
CN114466655A (zh) * 2019-08-20 2022-05-10 永生生技股份有限公司 心血管疾病的治疗

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5789147A (en) * 1994-12-05 1998-08-04 New York Blood Center, Inc. Method for concentrating white cells from whole blood by adding a red cell sedimentation reagent to whole anticoagulated blood
US20030215942A1 (en) * 2002-02-14 2003-11-20 Stemcyte, Inc. Undesignated allogeneic stem cell bank

Also Published As

Publication number Publication date
WO2006130812A3 (en) 2007-09-13
WO2006130812A2 (en) 2006-12-07
JP2008545755A (ja) 2008-12-18
HK1124484A1 (en) 2009-07-17
IL187641A0 (en) 2008-03-20
ATE551062T1 (de) 2012-04-15
EP1906729A4 (en) 2009-08-12
AU2006252363A1 (en) 2006-12-07
EP1906729B1 (en) 2012-03-28
RU2007148802A (ru) 2009-07-20
CA2609266A1 (en) 2006-12-07
MX2007015201A (es) 2008-03-14
EP1906729A2 (en) 2008-04-09
KR20080027295A (ko) 2008-03-26

Similar Documents

Publication Publication Date Title
IL187641A0 (en) Umbilical cord blood compositions
Xu et al. Metformin ameliorates ionizing irradiation-induced long-term hematopoietic stem cell injury in mice
Wang et al. The therapeutic potential of umbilical cord mesenchymal stem cells in mice premature ovarian failure
Showel et al. Advances in treating acute myeloid leukemia
Shrestha et al. Enhanced healing of diabetic wounds by subcutaneous administration of human umbilical cord derived stem cells and their conditioned media
Pradier et al. Human bone marrow stromal cells and skin fibroblasts inhibit natural killer cell proliferation and cytotoxic activity
Oliansky et al. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of adult acute lymphoblastic leukemia: update of the 2006 evidence-based review
CN101848991A (zh) 分离的细胞群
AR015926A1 (es) Celulas modificadas geneticamente y su utilizacion en la profilaxis o terapia de enfermedades
Yun et al. Reactive oxygen species induce MMP 12‐dependent degradation of collagen 5 and fibronectin to promote the motility of human umbilical cord‐derived mesenchymal stem cells
WO2004104166A3 (en) Administration of hyaluronic acid to enhance the function of transplanted stem cells
ES2422739T3 (es) Composición para el diagnóstico, prevención o tratamiento de enfermedades relacionadas con células que expresan IL-8 o GRO-, que comprende MSC de UCB
WO2007024441A3 (en) Compositions of cells enriched for combinations of various stem and progenitor cell populations, methods of use thereof and methods of private banking thereof
BR112018072701A2 (pt) métodos de tratamento de leucemia mieloide aguda e mieloma múltiplo usando células exterminadoras naturais
Schepici et al. Mesenchymal stromal cells preconditioning: a new strategy to improve neuroprotective properties
Talbot et al. Sequential treatment for allogeneic hematopoietic stem cell transplantation in Fanconi anemia with acute myeloid leukemia
Rudnitsky et al. Mesenchymal stem cells and their derivatives as potential longevity-promoting tools
Wang et al. Administration of the Resveratrol Analogues Isorhapontigenin and Heyneanol‐A Protects Mice Hematopoietic Cells against Irradiation Injuries
Cao et al. Therapeutic benefits of mesenchymal stem cells in acute respiratory distress syndrome: potential mechanisms and challenges
NZ603442A (en) Treatment of proliferative diseases
ATE482720T1 (de) Verfahren zur herstellung von temperaturinduzierten tumorzell-lysaten zur verwendung als immunogene verbindungen
WO2018053618A1 (en) Methods of culturing mesenchymal stromal cells
BRPI0515428A (pt) terapia por injeção ao tumor de células dendrìticas (dcti)
Vargas-Torres et al. Towards chlorocytes for therapeutic intravascular photosynthesis
BRPI0707247A8 (pt) vacina para tumor compreendendo células tumorais alogênicas ou xenogênicas

Legal Events

Date Code Title Description
B06G Technical and formal requirements: other requirements [chapter 6.7 patent gazette]

Free format text: SOLICITA-SE A REGULARIZACAO DA PROCURACAO, UMA VEZ QUE BASEADO NO ARTIGO 216 1O DA LPI, O DOCUMENTO DE PROCURACAO DEVE SER APRESENTADO NO ORIGINAL, TRASLADO OU FOTOCOPIA AUTENTICADA.

B11Z Dismissal: petition dismissal - article 216, par 2 of industrial property law

Free format text: REFERENTE A PETICAO 020070170526/RJ DE 30/11/2007.

B06H Technical and formal requirements: requirement cancelled [chapter 6.8 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.7 NA RPI NO 2080 DE 16/11/2010 POR TER SIDO INDEVIDA.

B11M Decision cancelled [chapter 11.13 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 11.6.1 NA RPI NO 2135 DE 06/12/2011 POR TER SIDO INDEVIDA.

B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]